SCHEDULE 13D/A: M33 Growth Increases Stake in The Oncology Institute Through Private Placement

M33 Growth I LP, M33 Growth I GP LLC, and TOI M, LLC have increased their beneficial ownership in The Oncology Institute, Inc. to 19.99% through a recent private placement of common stock and warrants.

Summary

• Reporting Persons, M33 Growth I LP, M33 Growth I GP LLC, and TOI M, LLC, filed an Amendment No. 3 to Schedule 13D regarding their holdings in The Oncology Institute, Inc. (TOI).
• On March 26, 2025, M33 participated in a Private Investment in Public Equity (PIPE) transaction.
• M33 purchased 1,358,449 units, each comprising 2,716,898 shares of Common Stock and 1,358,449 warrants.
• The aggregate purchase price for M33's units was $2,999,998.77, at a price of $2.2084 per unit.
• The warrants have an exercise price of $1.1980 per share and are set to expire on March 26, 2030.
• Post-transaction, M33 Growth I LP and M33 Growth I GP LLC collectively beneficially own 17,543,172 shares, representing 19.99% of the outstanding common stock.
• TOI M, LLC beneficially owns 1,552,580 shares, representing 1.77% of the outstanding common stock.
• The total outstanding shares of The Oncology Institute, Inc. common stock as of March 26, 2025, are 87,759,739, which includes 12,006,510 shares issued in the PIPE Transaction.
• Warrants held by M33 contain a beneficial ownership limitation, preventing exercise if it would result in ownership exceeding 19.99% of outstanding shares; consequently, 235,978 additional shares from warrants are not currently exercisable.

Sentiment

Score: 7

Explanation: The document indicates a significant capital infusion for The Oncology Institute, Inc. through a PIPE transaction, with a major investor (M33 Growth) increasing its stake and demonstrating continued commitment. While there is dilution from new share issuance, the capital raise itself is a positive for the company's financial health and operations.

Positives

• Significant investment by M33 Growth, indicating continued confidence in The Oncology Institute, Inc.'s prospects.
• The PIPE transaction provides capital to the Issuer, which can support its operations and strategic initiatives.
• The warrants provide potential for future capital infusion to the company upon their exercise.

Negatives

• The beneficial ownership limitation on warrants (19.99%) restricts M33's immediate full exercise of all warrants, limiting their potential immediate increase in stake.
• The PIPE transaction involved the issuance of 12,006,510 new shares, which results in dilution for existing shareholders.

Risks

• Dilution risk for existing shareholders due to the issuance of 12,006,510 new shares in the PIPE transaction.
• The warrant exercise price of $1.1980 may not be favorable if the stock price falls below this level, potentially reducing the likelihood of warrant exercise.
• The 19.99% beneficial ownership limitation on warrants could restrict M33's ability to increase its stake further without triggering additional regulatory requirements or changes.

Future Outlook

The document primarily reports a past transaction (PIPE) and current beneficial ownership. It does not provide explicit forward-looking statements or guidance from the company or the reporting persons regarding future operations or financial performance, beyond the warrant expiry date.

Management Comments

• Gabriel Ling, as Managing Member of M33 Growth I LP, M33 Growth I GP LLC, and TOI M, LLC, certified that the information set forth in the statement is true, complete, and correct to the best of his knowledge and belief.

Industry Context

The document details a significant investment in an oncology institute, reflecting continued private investment interest in the healthcare and specialized medical services sector. Oncology remains a critical and growing area within healthcare, attracting capital through mechanisms like PIPE transactions, which are common for companies seeking to raise funds from institutional investors.

Stakeholder Impact

• Shareholders: Existing shareholders experienced dilution due to the issuance of new shares in the PIPE transaction. However, the capital raise could strengthen the company's financial position, potentially benefiting shareholders long-term.
• Company (The Oncology Institute, Inc.): Received a capital infusion from the PIPE transaction, which can be used for operations, growth, or debt reduction.
• M33 Growth (Investor): Increased its strategic stake and influence in the company, reinforcing its position as a key investor.

Key Dates

Recommendation

Keywords

Oncology, Investment, Private Placement, PIPE, Warrants, Shareholding, SEC Filing, Schedule 13D, M33 Growth, The Oncology Institute